Servier Canada announces the launch of VENIXXA™, an over-the-counter oral treatment to relieve signs and symptoms of chronic venous disease and hemorrhoids

Friday, November 10, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

LAVAL, QC, Nov. 10, 2017 /CNW Telbec/ - Servier Canada announces that VENIXXATM (micronized purified flavonoid

fraction, MPFF), is now available in pharmacies as an over-the-counter oral treatment for patients with mild-to-moderate chronic venous disease or hemorrhoidal disease. VENIXXATM has been extensively tested in various controlled trials and
large registries and is currently available in more than 33 countries around the world.

Chronic venous disease of the legs is characterized by signs and symptoms ranging from a sensation of heavy and/or painful legs, night cramps,1spider and varicose veins, edema or ulcers. In the Vein Consult Program2—an international, observational survey completed by 6232 general practitioners, it was estimated that approximately 74% of adults suffer from mild-to-moderate chronic venous disease. "As physicians, we have very few options available for these patients apart from mechanical treatments such as compression stockings and endovenous procedures. Although these are very good alternatives, a treatment that addresses the inflammatory process and loss of venous tone related to venous disease is welcome" stated Dr. Douglas Hill, President of the Canadian Society of Phlebology.

Hemorrhoids are a common condition among adults in North America; it is estimated that at least 50% of the population +50 years old has suffered from hemorrhoids at one point in their life. The most common signs and symptoms related to this disease are pain, bleeding and discomfort.3

Patients often experience a decline in their quality of life as each of these diseases progresses.4

Servier Canada The over-the-counter drug market is expanding in Canada, and Servier Canada is proud to enter this market. "The launch of VENIXXATM stems from Servier`s priority to provide effective and innovative treatment options, to Canadian patients. We will leverage our international expertise in vascular disease, to raise awareness of chronic venous disease, hemorrhoidal disease and their consequences, as well as to work with health care providers to ensure that patients are provided with appropriate care." stated Frederic Fasano, Chief Executive Officer of Servier Canada.

Servier is an international pharmaceutical company governed by a non-profit foundation with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs 21 000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs.

Servier Canada was established in 1978 in Laval, Quebec and employs over 300 people across Canada. Servier Canada is currently marketing medicines in Cardiology, Hematology and Diabetes, and will soon market oncology products indicated as treatment options in hematological malignancies. For additional information please visit our website at

________________________________1Wittens C, Davies AH, Bækgaard N, et al. Editor's Choice - Management of Chronic Venous Disease. Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). J Vasc Endovasc Surg. 2015 Jun;49(6):6782Rabe E, et al. Epidemiology of chronic venous disorders in geographically diverse populations: results from the vein Consult Program. Int Angiol. 2012;31:105–115.3Mayo Clinic. Hemorrhoidal disease: Diagnosis and management. Accessed June 2017 from: Sanchez FS, Sanchez Nevarez I, Gonzalez-Porras JR, et al. Quality of life in patients with chronic venous disease: influence of the socio-demographical and clinical factors. Int Angiol. 2013;32(4):433-441.


SOURCE Servier Canada Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store